NuGen Medical Devices Inc. NGMD.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -76.88% | -77.89% | -79.66% | -93.54% | 46.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -76.88% | -77.89% | -79.66% | -93.54% | 46.79% |
| Cost of Revenue | -73.44% | -78.30% | -73.22% | -95.06% | 52.38% |
| Gross Profit | -79.17% | -77.56% | -85.13% | -92.02% | 43.28% |
| SG&A Expenses | 18.13% | 46.88% | 10.26% | -46.23% | 59.54% |
| Depreciation & Amortization | -84.54% | 10.56% | 26.99% | -- | 1.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.75% | 34.04% | -0.07% | -54.32% | 45.93% |
| Operating Income | -2.49% | -49.63% | -38.06% | 44.53% | -45.91% |
| Income Before Tax | 57.04% | -208.28% | -1,121.18% | 37.15% | -141.63% |
| Income Tax Expenses | -90.00% | -- | 1,342.86% | -141.77% | -- |
| Earnings from Continuing Operations | 57.10% | -208.55% | -1,122.88% | 37.52% | -142.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.10% | -208.55% | -1,122.88% | 37.52% | -142.06% |
| EBIT | -2.49% | -49.63% | -38.06% | 44.53% | -45.91% |
| EBITDA | -20.61% | -58.65% | -44.44% | 48.67% | -59.83% |
| EPS Basic | 56.76% | -208.33% | -1,064.71% | 40.00% | -131.25% |
| Normalized Basic EPS | 56.52% | -210.00% | -291.30% | 40.32% | -119.05% |
| EPS Diluted | 56.76% | -208.33% | -1,064.71% | 40.00% | -131.25% |
| Normalized Diluted EPS | 56.52% | -210.00% | -291.30% | 40.32% | -119.05% |
| Average Basic Shares Outstanding | 0.00% | 0.25% | 3.45% | 4.47% | 5.17% |
| Average Diluted Shares Outstanding | 0.00% | 0.25% | 3.45% | 4.47% | 5.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |